Source link : https://www.newshealth.biz/health-news/novel-drug-simplifies-cystic-fibrosis-treatment-regimen/
TOPLINE: Vanzacaftor-tezacaftor-deutivacaftor, a novel therapeutic, once-daily drug, demonstrates noninferiority to elexacaftor-tezacaftor-ivacaftor (the twice-daily, standard-of-care drug) in lung function improvement with an acceptable safety profile in patients with cystic fibrosis. METHODOLOGY: Researchers conducted two randomized, double-blind phase 3 trials (SKYLINE VX20-121-102 and VX20-121-103) to compare the efficacy and safety of vanzacaftor-tezacaftor-deutivacaftor with those of standard-of-care elexacaftor-tezacaftor-ivacaftor […]
Author : News Health
Publish date : 2025-01-22 08:44:45
Copyright for syndicated content belongs to the linked Source.
inHealth